Drugs / αPD1-MSLN-CAR T cells
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05373147 | Oct 2020 → Feb 2023 | cancer | Shanghai Mengchao Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04489862 | May 2020 → Jun 2022 | mesothelioma, non-small cell lung carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 0 | NCT04503980 | Mar 2020 → Mar 2021 | colorectal cancer, ovarian cancer | Shanghai Cell Therapy Group Co.,Ltd | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05089266 | Nov 2021 → Jul 2024 | colorectal cancer | Shanghai Cell Therapy Group Co.,Ltd | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05944185 | Sep 2023 → Sep 2024 | neoplasm | Shanghai Cell Therapy Group Co.,Ltd | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | αPD1-MSLN-CAR T Cells | “αPD1-MSLN-CAR T Cells” NCT05089266 ↗ |
| Modality | Cell therapy | “autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies” NCT04489862 ↗ |
| Route | Intravenous | “one dose treatment with αPD1-MSLN-CAR T cells by intravenous (IV) injection” NCT04489862 ↗ |
| Target | MSLN | “mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells” NCT04489862 ↗ |